by Ruel T, Penazzato M, Zech JM, Archary M, Cressey TR, Goga A, Harwell J, Landovitz RJ, Lain MG, Lallemant M, Namusoke-Magongo E, Mukui I, Permar SR, Prendergast AJ, Shapiro R, Abrams EJ. Global Health: Science and Practice 2023. doi: doi.org/10.9745/GHSP-D-22-00401
Summary: In 2021, the WHO and the International Maternal Paediatric Adolescent AIDS Clinical Trials Network convened a workshop to accelerate the research and development of new agents and approaches to postnatal prophylaxis. The authors of this article present the data reviewed and the ideas generated at the second meeting of the series. In the short term, the best route forward appears to be evaluating universal and risk-stratified approaches that combine legacy and novel antiretroviral drugs that are also used for treatment and passive immunization approaches. In the long term, pipeline products that allow for less frequent administration could open the door to a more integrated approach where a single strategy could be administered across the risk spectrum perinatally and postnatally.
